Literature DB >> 35603477

Reply.

Antonio D'Alessio1,2, Claudia Angela Maria Fulgenzi1,3, David J Pinato1,4.   

Abstract

Entities:  

Year:  2022        PMID： 35603477     DOI： 10.1002/hep.32587

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.298


× No keyword cloud information.
  1 in total

1.  Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.

Authors:  Takeshi Hatanaka; Satoru Kakizaki; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Noritomo Shimada; Kazuhito Kawata; Hisashi Kosaka; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Takashi Kumada
Journal:  Hepatol Int       Date:  2022-09-09       Impact factor: 9.029
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.